BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety disorder, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat anxiety related disorders, including benzodiazepine dependency. It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
